Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Per oral vs subcutaneous methotrexate in early rheumatoid arthritis
2024-512453-25-00Phase 4Authorised
- Sponsor
- Region Västerbotten
- Start
- Jul 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of methotrexate in rheumatoid arthritis (RA) (2 arms), sponsored by Region Västerbotten. Primary endpoint: DAS28. Planned start Jul 2024; status: authorised.
02
Drugs
methotrexate
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2024-512453-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512453-25-00.